CD274 and neoplasm: Patients are tested for PD-L1 positivity before treatment which is defined as a tumor proportion score >1% or a combined positive score of >10.42 Atezolizumab is an anti-PD-L1-antibody that was approved by the FDA through accelerated approval for treating unresectable locally advanced and metastatic TNBC, which showed an increase in OS when administered in combination with chemotherapy in IMpassion130 clinical trial.43 The continued approval was based on the forthcoming results from the following study Impassion131, which had the same study design but replaced Abraxane for Taxol.